|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Jim Cramer and Novartis CEO Vas Narasimhan discuss how the drugmaker is refocusing its business to leverage new-age treatments and potential cures.
Endocyte, Inc. (ECYT) (“Endocyte”), a biopharmaceutical company developing targeted therapeutics for cancer treatment, today announced that at its Special Meeting of Stockholders held earlier today, Endocyte’s stockholders approved the adoption of the merger agreement pursuant to which Novartis AG will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash.
On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62. Arrowhead Pharmaceuticals stock rose from $3.68 at the close of market on December 29, 2017, to reach $15.19 at the close of market on December 12, reflecting a ~313% year-to-date rise.
Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]
Endocyte (ECYT) stock rose from $4.28 at the close of market on December 29, 2017, to $23.60 at the close of market on November 20, 2018, representing ~451% YTD (year-to-date) growth. Endocyte hit its 52-week high of $23.89 on November 5. In October, Endocyte announced a merger with Novartis (NVS).
NEW YORK, Nov. 16, 2018 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Southern District of New York, Case No. 1:18-cv-10392-JMF, on behalf of public common shareholders of Endocyte, Inc. ("Endocyte" or the "Company") (ECYT) who held Endocyte securities on the record date November 15, 2018 (the "Class Period"), and have been harmed by Endocyte and its board of directors' (the "Board") alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the sale of the Company to affiliates of Novartis AG ( the "Proposed Merger").
Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Endocyte (ECYT) delivered earnings and revenue surprises of -6.25% and 330.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the West Lafayette, Indiana-based company said it had a loss of 17 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced financial results for the third quarter ended Sept. 30, 2018 and provided an operational update. “177Lu-PSMA-617’s value as a potential treatment for patients with mCRPC has been reinforced in both our regulatory interactions and our entry into a merger agreement with Novartis AG, along with our longstanding interactions with patients and physicians in the prostate cancer community,” said Mike Sherman, president and CEO of Endocyte. Announced on October 18, 2018, our entry into an agreement and plan of merger with Novartis AG (Novartis), subject to the terms and conditions of which Novartis will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash.
Bayer's (BAYGn.DE) chief executive reaffirmed his support for a corporate structure made up of healthcare, crop science and animal health businesses, after analysts called for a breakup to shore up its flagging share price. Shares in drugmaker Bayer, which bought Monsanto for $63 billion (£48.4 billion) , have lost more than 25 percent since a U.S. jury in August found its glyphosate-based weedkillers responsible for a man's terminal cancer, with more than 8,700 plaintiffs also seeking damages. "We have announced our strategy in September 2014, which has not changed to date," Chief Executive Werner Baumann told journalists in St. Louis at the former Monsanto headquarters where Bayer's seed business is now based.
NEW YORK , Nov. 1, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 18) Endocyte, Inc. (NASDAQ: ECYT )( announced a deal to ...
NEW YORK, NY / ACCESSWIRE / October 19, 2018 / Shares of biotech stocks Proteostasis Therapeutics and Endocyte were seeing big gains on different exciting announcements. Proteostasis announced encouraging preliminary results while traders learned that Endocyte will be purchased by Novartis for $2.1 billion. Proteostasis Therapeutics, Inc. shares closed up 447.62% on Thursday on skyrocket volume of about 94 million shares.
All three of the major indices sold off into the close on Thursday, and the selling accelerated midday after Treasury Secretary Steven Mnuchin announced that he will not be attending a summit in Saudi Arabia.
Expanding further into the increasingly competitive field of oncology, Swiss drugmaker Novartis AG (NVS) announced on Thursday morning it is buying biopharmaceutical company Endocyte Inc. (ECYT) in a deal valued at $2.1 billion. Warning! GuruFocus has detected 3 Warning Signs with NVS. According to the terms of the all-cash agreement, Novartis will pay $24 per share for the West Lafayette, Indiana-based company, a 54% premium to the stock's closing price on Oct. 17.